Opinion|Videos|August 14, 2024
Engaging mFARS Scale to Monitor Friedreich Ataxia Progression
An expert in Friedreich's ataxia evaluates the mFARS (modified Friedreich's Ataxia Rating Scale) measurement tool, highlighting its advantages and limitations, while also exploring alternative assessment methods for tracking disease progression.
Advertisement
Episodes in this series
- The mFARS measurement tool is frequently reserved for clinical trials due to its time-consuming nature. What alternative tool do you employ to monitor disease progression, and have you observed any shifts in these metrics following the approval of omaveloxolone?
- What is the clinical value of omaveloxolone in patients with wheelchair dependence?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
Tozorakimab Cuts COPD Exacerbations Up to 34% in Phase 3 Trials
2
Tozorakimab Curbs Multiple COPD Inflammatory Pathways, ERS Data Show
3
Trump Admin Awards $106M to Expand Rural Health Care in NY, RI, MI
4
AI Model Flags Colorectal Cancer on Routine Noncontrast CT Scans
5